david you are far from correct
you said
GE is not involved with the company, but only supplies them with product which they use in their research
CytoGenix and GE Healthcare Ink BioDefense Support Agreement
12/27/2005 4:18:01 PM
HOUSTON, Dec 27, 2005 (BUSINESS WIRE) -- CytoGenix, Inc. ( CYGX ) announced today the signing of a contract with the Fast Trak BioDefense group of GE Healthcare, a unit of General Electric Company ( GE ).
GE Healthcare's Fast Trak BioDefense group has a diverse staff of highly qualified technical and regulatory experts who will collaborate with CytoGenix in seeking, obtaining and executing bio-defense related federal contracts.
Frank Vazquez, CytoGenix, Inc. Executive Vice President and COO commented, "Our association with GE Healthcare, a $14 Billion entity of GE, as partners in competing for federal research projects sends a very positive message to grant reviewers and granting agencies at the Department of Homeland Security, the Department of Defense and the Department of Health and Human Services. We are very excited about this relationship and expect to see very positive results soon."
Dr. Sandy Weinberg, Senior Director, Fast Trak BioDefense GE Healthcare commented, "CytoGenix's innovative DNA vaccine and antimicrobial technology can be applied to many critical needs in bio-defense. The company has an excellent team of scientists, and we expect with that with our assistance we can attain substantial results."
About GE Healthcare: GE Healthcare is a $14 billion unit of General Electric Company ( GE ) that is headquartered in the United Kingdom. Worldwide, GE Healthcare employs more than 42,500 people committed to serving healthcare professionals and their patients in more than 100 countries. For more information about GE Healthcare, visit the company's website at www.gehealthcare.com.
About CytoGenix: CytoGenix, Inc. is a Houston-based biopharmaceutical company that develops and markets innovative products and services based on its proprietary ssDNA expression technology. The company has developed a breakthrough synthetic process for large-scale production of high purity DNA at a fraction of the cost of traditional fermentation methods. CytoGenix currently has one issued US patent and 41 international or US pending patent applications claiming methods and materials in connection with this platform technology.
gdepc
